Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment

References

• Reid-Arndt SA, Yee A, Perry MC, et al. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol. 2009;27(4):415–434.
   PubMed Web of Science ®Google Scholar
• Jacola LM, Edelstein K, Liu W, et al. Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study. Lancet Psychiatry. 2016;3(10):965–972.
   PubMed Web of Science ®Google Scholar
• Hshieh TT, Jung WF, Grande LJ, et al. Prevalence of cognitive impairment and association with survival among older patients with hematologic cancers. JAMA Oncol. 2018;4(5):686–693.
   PubMed Web of Science ®Google Scholar
• Dos Santos M, Lange M, Gervais R, et al. Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence. Support Care Cancer. 2019;27(9):3573–3581.
   PubMed Web of Science ®Google Scholar
• Joly F, Giffard B, Rigal O, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage. 2015;50(6):830–841.
   PubMed Web of Science ®Google Scholar
• Janelsins MC, Heckler CE, Peppone LJ, et al. Longitudinal trajectory and characterization of cancer-related cognitive impairment in a Nationwide Cohort Study. J Clin Oncol. 2018.
   Google Scholar
• Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol. 2017;35(5):506–514.
   PubMed Web of Science ®Google Scholar
• Williams AM, Shah R, Shayne M, et al. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol. 2018;314:17–23.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201.
   PubMed Web of Science ®Google Scholar
• Zent CS, Kay NE. Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma. 2011;52(8):1425–1434.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–708.
   PubMed Web of Science ®Google Scholar
• Weintraub S, Dikmen SS, Heaton RK, et al. Cognition assessment using the NIH Toolbox. Neurology. 2013;80(11, Suppl. 3):S54–S64.
   PubMed Web of Science ®Google Scholar
• Reynolds CR. Comprehensive trail-making test professional manual. Austin (TX): Pro-Ed; 2002.
   Google Scholar
• Brandt JB. Hopkins verbal learning test revised professional manual. Lutz (FL): Psychological Assessment Resources; 2001.
   Google Scholar
• Ruff RM, Light RH, Parker SB, et al. Benton Controlled Oral Word Association Test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329–338.
   PubMed Web of Science ®Google Scholar
• Von Ah D, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy-cognitive function instrument. J Pain Symptom Manage. 2015;49(4):697–706.
   PubMed Web of Science ®Google Scholar
• NIH. NIH toolbox scoring and interpretation guide for the iPad. Chicago (IL): National Institutes of Health and Northwestern University; 2016.
   Google Scholar
• Bell ML, Dhillon HM, Bray VJ, et al. Important differences and meaningful changes for the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog). J Patient Rep Outcomes. 2018;2(1):48.
   Google Scholar
• Wefel JS, Kesler SR, Noll KR, et al. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2):123–138.
   PubMed Web of Science ®Google Scholar
• Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–325.
   PubMed Web of Science ®Google Scholar
• Spielberger CS, Sysdeman J, Owen AE, et al. The use of psychological testing for treatment planning and outcomes assessment: measuring anxiety and anger with the State-Trait Anxiety Inventory (STAI) and the State-Trait Anger Expression Inventory (STAXI). In: Maruish ME, editor. The use of psychological testing for treatment planning and outcomes assessment. Mahwah (NJ): Lawrence Erlbaum Associates, Inc.; 1999.
   Google Scholar
• McCallum J, Mackinnon A, Simons L, et al. Measurement properties of the Center for Epidemiological Studies Depression Scale: an Australian community study of aged persons. J Gerontol B Psychol Sci Soc Sci. 1995;50:S182–S189.
   PubMed Web of Science ®Google Scholar
• Jacobs SR, Jacobsen PB, Booth-Jones M, et al. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage. 2007;33(1):13–23.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B (Methodol). 1995;57(1):289–300.
   Web of Science ®Google Scholar
• Williams AM, Baran AM, Meacham PJ, et al. Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma. 2018;59(3):625–632.
   PubMed Web of Science ®Google Scholar
• Koleck TA, Bender CM, Sereika SM, et al. Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. Cancer Med. 2017;6(2):339–348.
   PubMed Web of Science ®Google Scholar
• Else M, Cocks K, Crofts S, et al. Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leuk Lymphoma. 2012;53(7):1289–1298.
   PubMed Web of Science ®Google Scholar
• Zimmer P, Mierau A, Bloch W, et al. Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine. Leuk Lymphoma. 2015;56:347–352.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126–135.
   PubMed Web of Science ®Google Scholar
• Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223–232.
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.
   PubMed Web of Science ®Google Scholar
• Carpenter CR, Bassett ER, Fischer GM, et al. Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer’s Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8. Acad Emerg Med. 2011;18:374–384.
   PubMed Web of Science ®Google Scholar
• Jain N, O’Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015;126(4):463–470.
   PubMed Web of Science ®Google Scholar